Article
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
European journal of cancer care - 1 Nov 2017
Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M
Abstract excerpt
In order to improve outcomes, identification of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genes has become crucial in advanced non-small-cell lung cancer (NSCLC). The aim of the present study is to analyse time trends and frequency of testing, factors affecting testing as well as prevalence of mutations in the Swiss population. We analysed EGFR and ALK testing in a cohort of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.